“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
In this briefing Sabah Meddings of the Sunday Times and healthcare analyst Andy Smith discuss his recent note, Trial outcomes and value – explaining contemporary clinical trial issues. They discuss how the detail of pharmaceutical and biotechnology company clinical trials is relevant to investors. They also touch on the debate surrounding the confidentiality of interactions between drug sponsors and regulators and whether this is material to investors.
Get access to the very latest content matched to your personal investment style.